Ticker News
$SPRC News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
SciSparc unit pursues FDA orphan status for Tourette drug, hires RK Strategies
SciSparc's majority-owned NeuroThera is pursuing FDA Orphan Drug Designation for SCI-110 (adult Tourette syndrome) and has retained RK Strategies to support U.S. government and public affairs engagement. SCI-110 is a cannabinoid-based combo now in a Phase IIb program at Yale, Hannover and Tel Aviv after a Phase IIa that showed an average 21% tic reduction, so orphan status could boost regulatory/commercial profile but clinical benefit remains preliminary.
SciSparc names AI expert Carmel Domshlak to advisory board as it targets Agentic AI
SciSparc (SPRC) appointed Prof. Carmel Domshlak to its new Scientific Advisory Board for AI and Cybersecurity to bolster the company’s pivot toward the Agentic AI market. Domshlak is a widely recognized researcher in automated planning, multi-agent systems and decision-making (multiple ICAPS awards), and the company says it is evaluating opportunities and in discussions with several Agentic AI players but disclosed no deals or financial terms.
NeuroThera/Clearmind US patent application published for MDMA+PEA combo to treat PTSD
NeuroThera (SciSparc subsidiary) and Clearmind published a U.S. patent application covering a combination of MDMA and N-acylethanolamines (e.g., PEA) for treating PTSD, anxiety and eating disorders, expanding their joint IP portfolio and describing potential impacts on MDMA’s potency, dosing, side-effect profile and therapeutic window. The publication coincides with the FDA finalizing guidance that explicitly includes MDMA in psychedelic drug development—providing regulatory context for the IP but the filing is an application (not a granted patent) and the release contains no clinical efficacy or safety data.
SciSparc subsidiary NeuroThera wins Japanese patent for paracetamol + N‐acylethanolamine combo
SciSparc said its majority-owned subsidiary NeuroThera Labs (NTLX) was granted a Japanese patent titled "Compositions and Methods for Potentiating Derivatives of 4‐Aminophenols," covering proprietary combinations of 4‐aminophenol derivatives (including paracetamol) with N‐acylethanolamines. The company says the combos are intended to enhance analgesic/antipyretic effects and may allow lower dosing to mitigate dose‐related side effects, and the grant expands NeuroThera/SciSparc’s IP footprint in Japan — commercial value still depends on clinical data, regulatory approvals, and commercialization steps.
SciSparc/NeuroThera launches Phase IIb SCI-110 Tourette trial site at Yale
SciSparc’s majority-owned NeuroThera has opened a Phase IIb site at the Yale Child Study Center to evaluate SCI-110, an oral cannabinoid formulation (dronabinol + palmitoylethanolamide) for adults with Tourette syndrome in a randomized, double-blind, placebo-controlled crossover trial measuring tic change by the Yale Global Tic Severity Scale at weeks 12 and 26. The study is part of a multicenter program (also in Germany and Israel) and builds on a Phase IIa that reported a 21% average tic reduction, so a positive Phase IIb could materially de-risk development—but efficacy to date is modest and the trial is ongoing.
NeuroThera demos end-to-end hybrid quantum-classical workflow for clinical data (simulation)
SciSparc said its subsidiary NeuroThera’s quantum sampling platform demonstrated a complete end-to-end hybrid quantum‐classical workflow for processing clinical trial and biomedical data, covering secure ingestion through quantum-enabled analysis to clinically interpretable outputs. The run was executed in a quantum simulation environment; the company says it will scale datasets, optimize algorithms and run performance studies but provided no real‐hardware benchmarks or deployment timeline.
NeuroThera validates quantum sampling workflow for clinical data on S&P 500 hybrid platform
SciSparc’s majority-owned NeuroThera Labs completed internal validation of a proprietary quantum sampling workflow that represents continuous probability distributions as quantum-operable energy landscapes and applies Quantum Markov Chain Monte Carlo in a hybrid quantum-classical architecture using an S&P 500 company platform. The company says this validated component supports the Platform’s ability to tackle large-scale clinical and biomedical datasets and is being advanced via CliniQuantum (NeuroThera holds 54.01%), but this is an early internal technical validation—not clinical or production performance data.
SciSparc to Target Agentic AI Market, Forms AI & Cybersecurity Scientific Advisory Board
SciSparc (SPRC) said its board has decided to target the agentic AI market and has formed a Scientific Advisory Board focused on artificial intelligence and cybersecurity while evaluating opportunities and holding discussions with several agentic-AI companies. The firm remains a clinical-stage cannabinoid/pharma developer via majority-owned NeuroThera and cautioned the AI initiative is exploratory with no committed deals, timelines, or financial details.
NeuroThera (SciSparc) closes acquisition of ~54% of CliniQuantum for 56.6M shares; up to $2.5M earn-outs
SciSparc's majority‐owned NeuroThera Labs closed the acquisition of approximately 54% of CliniQuantum by issuing 56,600,000 NeuroThera common shares (≈CAD$9.46M based on the 20‐day VWAP) to CliniQuantum shareholders. The deal includes up to US$2.5M in milestone‐based earn‐outs payable in cash and/or shares over three years (tied to patent filings and fundraising), an amendment that sets a CAD$0.05 floor on any earn‐out share issuances, and transfers exclusive rights to a quantum simulation/Monte Carlo clinical‐trial analytics license (currently backed by a single US provisional patent application).
NeuroThera (SciSparc unit) closes acquisition of ~54% of CliniQuantum
SciSparc said its majority-owned subsidiary NeuroThera closed the purchase of ~54% of CliniQuantum by issuing 56.6M NeuroThera shares (valued at ~CAD 9.46M based on VWAP) to sellers and agreeing to up to US$2.5M in earn-outs payable in cash and/or shares. CliniQuantum brings an exclusive license to a quantum simulation/Monte Carlo platform (supported by a single U.S. provisional patent) aimed at improving clinical-trial subgroup identification—potentially useful for refining NeuroThera's trial analytics but still early-stage and contingent on milestone delivery.
NeuroThera (NTLX) gets conditional TSXV approval to buy ~54% of CliniQuantum
NeuroThera Labs, majority-owned by SciSparc (SPRC), received conditional TSX Venture Exchange approval to acquire ~54% of CliniQuantum in exchange for 56.6M NeuroThera shares (≈$9.46M based on 20-day VWAP); the Consideration Shares will be placed in escrow and the SPA was amended to include a $0.05 floor on future earn-out share issuances and lock-ups. CliniQuantum’s main asset is an exclusive license to a single U.S. provisional patent for quantum Monte Carlo simulation methods aimed at improving clinical-trial subgroup identification, and closing remains conditional on obtaining an Israeli tax ruling and final TSXV acceptance (outside date extended to June 1, 2026).
NeuroThera/SciSparc gets conditional TSXV approval to buy ~54% of CliniQuantum
NeuroThera Labs (majority‐owned by SciSparc) received conditional TSX Venture approval to acquire ~54% of CliniQuantum in exchange for 56.6M NeuroThera shares (valued at ~ $9.46M based on a 20‐day VWAP). CliniQuantum's primary asset is an exclusive license to a US provisional patent for quantum simulation/quantum Monte Carlo methods aimed at improving clinical trial subgroup identification; closing remains conditional on an Israeli tax ruling and final TSX acceptance, and the Consideration Shares will be placed in escrow with lock‐ups and an earn‐out share floor of $0.05.